Man­u­fac­tur­ing roundup: FDA, Swissmedic ink deal on phar­ma GMP; SK biotech con­tracts with Charles Riv­er for RNA ther­a­py 

The reg­u­la­to­ry agen­cies of the US and Switzer­land signed an agree­ment last week, al­low­ing them to uti­lize each oth­er’s good man­u­fac­tur­ing prac­tice (GMP) in­spec­tions of phar­ma­ceu­ti­cal man­u­fac­tur­ing fa­cil­i­ties — and by­pass du­pli­cate in­spec­tions.

This is the newest agree­ment that the FDA has with for­eign en­ti­ties, such as the EU and the UK. These agree­ments are thanks to a 2012 law that al­lowed the FDA to rec­og­nize in­spec­tions con­duct­ed by cer­tain for­eign reg­u­la­tors de­ter­mined to be ca­pa­ble of in­spec­tions that met US re­quire­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER